VedaBio is pioneering advancements in molecular detection through its innovative CRISPR Cascade™ platform, which enables ultra-rapid and highly accurate detection of multiplexed analytes without the need for target amplification. This technology utilizes engineered CRISPR enzymes to specifically identify molecular targets and amplify detection signals in a positive feedback loop, resulting in analytical turnaround times of less than one minute. The platform's design allows for massive multiplexing capabilities, enabling the simultaneous analysis of multiple targets within a single reaction, which is a significant improvement over traditional PCR and other amplification methods.

The CRISPR Cascade™ platform is characterized by its ability to generate robust signals through the combined use of multiple CRISPR enzymes, blocked nucleic acid sequences, and reporter molecules, all while eliminating the constraints associated with target amplification. This flexibility allows for rapid reprogramming to accommodate new targets, facilitating swift product development. VedaBio's technology is positioned to transform various industries, including healthcare, pharmaceuticals, and environmental monitoring, by providing cost-effective, high-performance solutions for molecular detection and diagnostics.

United States

Veda is derived from the Sanskrit word for the creation of knowledge. With our team of industry leading experts, we operate at the forefront of scientific innovation to push the limits of what’s possible in the field of molecular detection. 

VedaBio is unlocking a universe of possibilities in molecular biology with a breakthrough platform for near-instant molecular detection of highly multiplexed analytes, delivering best-in-class accuracy without the need for target amplification. 

VedaBio

Company Details